KR20150003824A - 당뇨병 치료 및/또는 이식 후 췌장섬 생존 촉진 방법 - Google Patents

당뇨병 치료 및/또는 이식 후 췌장섬 생존 촉진 방법 Download PDF

Info

Publication number
KR20150003824A
KR20150003824A KR1020147032172A KR20147032172A KR20150003824A KR 20150003824 A KR20150003824 A KR 20150003824A KR 1020147032172 A KR1020147032172 A KR 1020147032172A KR 20147032172 A KR20147032172 A KR 20147032172A KR 20150003824 A KR20150003824 A KR 20150003824A
Authority
KR
South Korea
Prior art keywords
smad7
seq
diabetes
cells
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020147032172A
Other languages
English (en)
Korean (ko)
Inventor
지오반니 몬테레온
피터 부흐발트
루카 인베라르디
안토넬로 필레기
카밀로 리코르디
앨리스 토메이
Original Assignee
노그라 파마 리미티드
유니버시티 오브 마이애미
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노그라 파마 리미티드, 유니버시티 오브 마이애미 filed Critical 노그라 파마 리미티드
Publication of KR20150003824A publication Critical patent/KR20150003824A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147032172A 2012-04-18 2013-04-18 당뇨병 치료 및/또는 이식 후 췌장섬 생존 촉진 방법 Abandoned KR20150003824A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
US61/625,904 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
KR20150003824A true KR20150003824A (ko) 2015-01-09

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147032172A Abandoned KR20150003824A (ko) 2012-04-18 2013-04-18 당뇨병 치료 및/또는 이식 후 췌장섬 생존 촉진 방법

Country Status (14)

Country Link
US (3) US10081809B2 (https=)
EP (1) EP2839004B1 (https=)
JP (2) JP6348484B2 (https=)
KR (1) KR20150003824A (https=)
CN (2) CN107252492A (https=)
AU (1) AU2013249191B2 (https=)
CA (1) CA2870547A1 (https=)
DK (1) DK2839004T3 (https=)
ES (1) ES2732252T3 (https=)
IN (1) IN2014DN08158A (https=)
MX (1) MX370149B (https=)
NZ (1) NZ630914A (https=)
RU (1) RU2667960C2 (https=)
WO (1) WO2013158868A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2704092T3 (es) * 2014-04-30 2019-03-14 Procter & Gamble Composición limpiadora
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3165593B1 (en) * 2015-10-29 2019-01-23 The Procter and Gamble Company Liquid detergent composition
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
US11584935B2 (en) * 2018-05-08 2023-02-21 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
AU2004263830B2 (en) * 2003-06-13 2008-12-18 Alnylam Pharmaceuticals, Inc. Double-stranded ribonucleic acid with increased effectiveness in an organism
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
ES2686708T3 (es) * 2008-04-18 2018-10-19 Baxter International Inc. Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
RU2593939C2 (ru) * 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2014229985B2 (en) 2013-03-15 2018-12-13 Nogra Pharma Limited Methods of treating colorectal cancer
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2017144689A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
AU2013249191B2 (en) 2019-01-03
MX2014012650A (es) 2015-04-08
CN104487574A (zh) 2015-04-01
AU2013249191A1 (en) 2014-10-09
US20150315573A1 (en) 2015-11-05
RU2014146170A (ru) 2016-06-10
US10081809B2 (en) 2018-09-25
CN104487574B (zh) 2017-07-07
EP2839004B1 (en) 2019-06-12
EP2839004A1 (en) 2015-02-25
JP2015514778A (ja) 2015-05-21
JP6348484B2 (ja) 2018-06-27
RU2667960C2 (ru) 2018-09-25
US20190136237A1 (en) 2019-05-09
WO2013158868A1 (en) 2013-10-24
JP2018131468A (ja) 2018-08-23
ES2732252T3 (es) 2019-11-21
US20200239884A1 (en) 2020-07-30
IN2014DN08158A (https=) 2015-05-01
NZ630914A (en) 2017-01-27
CA2870547A1 (en) 2013-10-24
DK2839004T3 (da) 2019-07-01
US10443056B2 (en) 2019-10-15
CN107252492A (zh) 2017-10-17
HK1207117A1 (en) 2016-01-22
MX370149B (es) 2019-12-03

Similar Documents

Publication Publication Date Title
US10443056B2 (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
KR101800333B1 (ko) 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정
DK2521556T3 (en) MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
KR101840512B1 (ko) Gcgr 발현의 안티센스 조절
EP3210611B1 (en) Methods of treating vascular inflammatory disorders
KR20150118180A (ko) 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
AU2011237426A1 (en) Modulation of CETP expression
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
EP3161126A1 (en) Methods for inducing insulin production and uses thereof
KR20170122769A (ko) 지방이상증 집단에서 아포지단백질 C-III (ApoCIII) 발현의 조절
Mahjoubin-Tehran et al. Decoys as potential therapeutic tools for diabetes
US20110034381A1 (en) Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)
HK1207117B (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
HK40036861A (en) Modulation of angiopoietin-like 3 expression

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180417

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190718

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200323

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee